Eltrombopag Tablet
FDA Label NDC 70771-1925

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Eltrombopag (NDC 70771-1925). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

NDC 70771-1925-3

Eltrombopag Tablets, 12.5 mg

30 Tablets

Rx only

12.5 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 01)

12.5 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 01)

NDC 70771-1926-3

Eltrombopag Tablets, 25 mg

30 Tablets

Rx only

25 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 02)

25 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 02)

NDC 70771-1927-3

Eltrombopag Tablets, 50 mg

30 Tablets

Rx only

50 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 03)

50 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 03)

NDC 70771-1928-3

Eltrombopag Tablets, 75 mg

30 Tablets

Rx only

75 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 04)

75 mg (5273da92 Fa13 4b26 B32f 63955b1983c3 04)

* Please review the disclaimer below.